Interactions between follicle-stimulating hormone and growth factors in modulating secretion of steroids and inhibin-related peptides by nonluteinized bovine granulosa cells.
Glister. C C; Tannetta. D S DS; Groome. N P NP; Knight. P G PG
Key Findings
- LR3 IGF‑I markedly increased production of inhibin A, activin A, follistatin, estradiol and modestly progesterone in bovine granulosa cells
- Low doses of LR3 IGF‑I combined with FSH enhanced hormone output, while the highest LR3 IGF‑I dose suppressed the FSH‑driven response
- EGF increased cell growth but blocked FSH‑induced hormone secretion
Practical Outcomes
- If you’re using IGF‑1 LR3, be aware it may affect estrogen‑related pathways, especially in females. Lower doses might synergize with natural FSH activity, but higher doses could blunt some hormonal effects. The results are from cow cells, so direct human recommendations are limited.
Summary
This study looked at how a lab‑made version of IGF‑1 (LR3 IGF‑I) and the hormone FSH affect hormone production in cow ovarian cells. LR3 IGF‑I alone boosted several hormones, especially estrogen‑related ones, and worked together with low doses of FSH, but at high doses it actually reduced some effects. The findings hint that IGF‑1 LR3 can influence ovarian hormone balance, but the work was done in isolated bovine cells, not humans.
Abstract
The aim was to investigate potential interactions between FSH and intraovarian growth factors in modulating secretion of inhibin A (inh A), activin A (act A), follistatin (FS), estradiol (E2), and progesterone (P4) by bovine granulosa cells cultured under conditions in which a nonluteinized FSH-responsive phenotype is maintained. Cells from 4- to 6-mm follicles were cultured in serum-free medium containing insulin (10 ng/ml) and androstenedione (10(-7) M), and effects of ovine FSH (0.037-3 ng/ml) were tested alone and in combination with insulin-like growth factors (IGF) (LR3 IGF-I analogue; 2-50 ng/ml) and epidermal growth factor (EGF; 0.1-10 ng/ml). Medium was changed every 48 h and cultures ended after 144 h, when cell number was determined. Between 48-96 h and 96-144 h, FSH promoted (P < 0.0001) increases in output of inh A (6-fold), act A (15-fold), FS (6-fold), and E2 (18-fold), with maximal responses (in parentheses) elicited by 0.33 ng/ml FSH during the final period. Higher FSH doses (1 and 3 ng/ml) gave reduced responses for each of the above hormones, whereas P(4) output was maximal (3-fold) at these doses. FSH promoted a slight increase in cell number ( approximately 1.7-fold; P < 0.001). LR3 IGF-I alone markedly increased (P < 0.0001) output of inh A (8-fold), act A (41-fold), FS (12-fold), and E2 (18-fold); this was accompanied by modest increases (P < 0.01) in P4 output ( approximately 2.5-fold) and cell number ( approximately 2-fold). Whereas FSH enhanced inh A, act A, FS, and E2 secretion evoked by lower doses of LR3 IGF-I, it suppressed (P < 0.001) the response to the highest dose. EGF alone promoted a 1.7-fold increase in cell number (P < 0.001) without affecting hormone release; however, it abolished (P < 0.001) FSH-induced secretion of inh A, act A, FS, and E2. Both FSH alone and LR3 IGF-I alone dose-dependently increased the act A:FS ratio ( approximately 3-fold; P < 0.005) and act A:inh A ratio (3-fold to 6-fold; P < 0.001), suggesting that both factors selectively raise activin "tone" and that this could be a key requirement for FSH and IGF-induction of follicular E2 production. This hypothesis was reinforced by the finding that addition of FS, to reduce the act A:FS ratio and sequester secreted activin, markedly suppressed (P < 0.001) FSH (3-fold)-, and LR3 IGF-I (2-fold)-induced E2 output.
Study Information
pubmed
2001
2001-10-01T00:00:00.000Z
10.1095/biolreprod65.4.1020
144
69